<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACRPO</journal-id><journal-title-group><journal-title>Asian Case Reports in Oncology</journal-title></journal-title-group><issn pub-type="epub">2169-8821</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACRPO.2018.74008</article-id><article-id pub-id-type="publisher-id">ACRPO-26444</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACRPO20180400000_98992342.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  宫颈端粒酶hTERC基因的表达和宫颈高危型HPV感染的型别的相关研究
  Research on Expression of Telomerase hTERC Gene and Infection of High Risk HPV in Cervix
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>梅</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宁</surname><given-names>旦</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>南宁市妇幼保健院，广西 南宁</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>175166684@qq.com(宁旦)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>08</month><year>2018</year></pub-date><volume>07</volume><issue>04</issue><fpage>51</fpage><lpage>55</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   宫颈癌是妇产科常见的恶性肿瘤之一，在宫颈癌的发生过程中，高危型人乳头瘤病毒(human papillomavirus, HPV)感染是重要的致瘤因素，HPV病毒有多个型别，常见为HPV16、18型感染。近几年的研究表明，宫颈癌的发生发展与人类染色体端粒酶基因扩增有联系。本文就端粒酶基因扩增和宫颈HPV感染的型别的相关研究进行综述。 Cervical cancer is one of the commonest malignant tumors in obstetrics and gynecology. In the development of cervical cancer, the infection of high risk human papillomavirus (HPV) is an im-portant tumorigenic factor, common for HPV16 and HPV18. Research in recent years shows that the occurrence and development of cervical cancer is related to the human chromosome telomerase gene amplification. In this paper, the correlation between telomerase gene amplification and cervical HPV infection is reviewed. 
 
</p></abstract><kwd-group><kwd>宫颈肿瘤，端粒酶，hTERC基因，HPV感染的型别, Cervical Cancer</kwd><kwd> Telomerase</kwd><kwd> hTERC Gene</kwd><kwd> HPV Infection</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>宫颈端粒酶hTERC基因的表达和宫颈高危型HPV感染的型别的相关研究<sup> </sup></title><p>杨梅，宁旦<sup>*</sup></p><p>南宁市妇幼保健院，广西 南宁</p><disp-formula id="hanspub.26444-formula1"><graphic xlink:href="//html.hanspub.org/file/1-2530086x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2017年12月28日；录用日期：2018年8月9日；发布日期：2018年8月16日</p><disp-formula id="hanspub.26444-formula2"><graphic xlink:href="//html.hanspub.org/file/1-2530086x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>宫颈癌是妇产科常见的恶性肿瘤之一，在宫颈癌的发生过程中，高危型人乳头瘤病毒(human papillomavirus, HPV)感染是重要的致瘤因素，HPV病毒有多个型别，常见为HPV16、18型感染。近几年的研究表明，宫颈癌的发生发展与人类染色体端粒酶基因扩增有联系。本文就端粒酶基因扩增和宫颈HPV感染的型别的相关研究进行综述。</p><p>关键词 :宫颈肿瘤，端粒酶，hTERC基因，HPV感染的型别</p><disp-formula id="hanspub.26444-formula3"><graphic xlink:href="//html.hanspub.org/file/1-2530086x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2530086x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2530086x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>宫颈癌是妇产科常见的恶性肿瘤之一，高危型HPV感染是已知的主要致病因素。HPV是一类双链、环行、嗜上皮性DNA病毒癌变过程中，在某些细胞内外因素的触发作用下，DNA整合到宿主细胞，导致宿主染色体不稳定，抑制抑癌基因 [<xref ref-type="bibr" rid="hanspub.26444-ref1">1</xref>] ，基因被抑制后发挥作用同时会对端粒酶基因及端粒酶的激活产生协同作用，端粒酶活化。</p><p>端粒酶的激活与细胞的无限增殖有关。在正常人体组织中，正常体细胞伴随分裂次数增加端粒逐渐缩短，当其长度短至临界点M1 (mortalphage1)时，细胞停止分裂，衰老并走向死亡；而当抑癌基因p53或Rb等突变时，可使细胞逃脱机体监控系统而越过M1期，再经过若干次分裂进入M2期(mortalphage2)；其中极少数细胞由于端粒酶的激活才成为永生细胞。端粒酶的激活是细胞走向永生化的必要途径，端粒酶活化是许多肿瘤发生的必经之路。端粒酶的激活是宫颈癌发生的早期事件，因此端粒酶的高表达可以作为宫颈癌及癌前病变的有效标志物。HPV已知有120多个亚型，高危型与子宫颈上皮内瘤变(cervical intraepithelial neoplasia CIN)：和宫颈癌有关。流行病学资料显示，在99.7%的宫颈癌组织中存在HPV-DNA，且主要为4种高危型HPV (16、18、31、45)感染，其中50%的宫颈癌与HPV16感染有关。HPV16在CIN3中阳性率为68%，在微浸润宫颈癌中为93%。 [<xref ref-type="bibr" rid="hanspub.26444-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.26444-ref3">3</xref>] 宿主染色体的不稳定性是由于HPV16整合插入还是HPV16协同？促进了其他类型HPV，引起了抑制抑癌基因更严重的不稳定性？本文对宫颈HPV感染的型别与端粒酶的表达及病变的进展有无关联进行相关研究。现概述如下：</p></sec><sec id="s4"><title>2. 端粒、端粒酶及端粒酶hTERC基因</title><p>端粒是现代生物学的研究热点，与肿瘤发生、基因表达调控、衰老有密切关系。端粒维持过程中有2个重要的蛋白—端粒相关蛋白和端粒酶。端粒相关蛋白是直接或间接与端粒结合的蛋白，在维持端粒稳定方面有重要作用。端粒酶是影响端粒长度的主要因素，它是一种特殊的逆转录核糖核蛋白酶，能以其自身的RNA为模板，向端粒末端添加(TTAGGG) n序列，以保持端粒的长度和细胞的生存，从而延长细胞的寿命甚至使其“永生” [<xref ref-type="bibr" rid="hanspub.26444-ref4">4</xref>] 。端粒酶在恶性肿瘤中的阳性表达率达90%~100%，而正常人体细胞几乎未检出端粒酶的活性，现在的观点认为癌细胞正是由于端粒酶活性增强使染色体端粒维持在一定长度而获得了永生和无限增殖 [<xref ref-type="bibr" rid="hanspub.26444-ref5">5</xref>] 。人类端粒酶包括三个主要组成部分，人端粒酶RNA (human telomerase RNA component, hTERC)，人类端粒酶相关蛋白1 (human telomerase associated protein1, hTEP1)，人类端粒酶逆转录酶(human te2 lomerase reverse transcriptase, hTERT)。其中hTERC为端粒酶的主体结构，含有编码端粒DNA的模板区、端粒酶蛋白结合区等。hTERC基因位于3号染色体长臂(3q26, 8q24, SE7) [<xref ref-type="bibr" rid="hanspub.26444-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.26444-ref7">7</xref>] ，是端粒酶延长端粒的模板，同时在介导端粒酶组装，活性调节等方面发挥着重要作用 [<xref ref-type="bibr" rid="hanspub.26444-ref8">8</xref>] 。有研究表明 [<xref ref-type="bibr" rid="hanspub.26444-ref9">9</xref>] ，敲除编码小鼠端粒酶RNA基因，端粒酶活性丧失，说明了hTERC基因在端粒酶活性调控中的必要作用。端粒酶特别是其催化亚基TERC在端粒延长过程中起着不可替代的作用，与胞永生化和癌变密切相关。</p></sec><sec id="s5"><title>3. 端粒酶及端粒酶hTERC基因和肿瘤的关系</title><p>端粒酶活化是许多肿瘤发生的必经之路，肿瘤的发生发展需要端粒酶参与。近年有关端粒酶与肿瘤关系的研究进展表明，在肿瘤细胞中端粒酶还参与对肿瘤细胞的凋亡和基因组稳定的调控过程，与端粒酶多重生物学活性相对应，肿瘤细胞中也存在复杂的端粒酶调控网络。通过蛋白质相互作用在翻译后水平对端粒酶活性及功能进行调控。一旦端粒酶被激活，它能延长缩短的端粒(缩短的端粒其细胞复制能力受限)，从而增强体外细胞的增殖能力，可能参与恶性转化。端粒酶的激活受控于hTERC基因，该基因扩增能够阻止细胞凋亡，导致肿瘤发生。因此hTERC基因是否扩增对研究宫颈癌发生发展及筛查治疗有重要作用。</p></sec><sec id="s6"><title>4. HPV与端粒酶及端粒酶基因</title><p>目前的研究已经表明，高危型人乳头瘤病毒感染是宫颈癌发病的首要因素。据统计80%的妇女一生中都会有过一次HPV感染，但由于人体自身具有免疫力，多数HPV会被清除，说明单纯的HPV感染并不能致瘤；仍需要其他因素的参与 [<xref ref-type="bibr" rid="hanspub.26444-ref10">10</xref>] ，这其中细胞内遗传性因素的改变可能具有更重要的意义。高危型HPV的持续感染；改变了宫颈上皮细胞的内外环境，引起细胞内非致死性的DNA损害，这种错误的不断积累导致宫颈上皮恶性转化的可能急剧上升，最终导致癌的发生。研究已经证实，HR-HPV在宫颈良性病变中以游离状态存在为主；癌变过程中，在某些细胞内外因素的触发作用下，DNA整合到宿主细胞，游离态HR-HPV数量减少，E2表达中断。当E2表达降低到一定程度时，失去对共同存在的整合形式的HR-HPV的抑制作用，癌基因E6/E7表达增加 [<xref ref-type="bibr" rid="hanspub.26444-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.26444-ref12">12</xref>] ，E6/E7的过表达则增加了整合的HR-HPV的选择优势和宿主染色体的不稳定性。在E6/E7的作用机制中，E7引起染色体异常复制，导致宿主染色体不稳定，使宿主细胞癌变，而E6能抑制抑癌基因p53介导的细胞凋亡，并激活端粒酶 [<xref ref-type="bibr" rid="hanspub.26444-ref13">13</xref>] 。亦有研究指出，p53基因被抑制后发挥作用的同时会对端粒酶基因及端粒酶的激活产生协同作用，促进癌症的发生。这提示HPV的致癌过程也与端粒酶及端粒酶基因密切相关 [<xref ref-type="bibr" rid="hanspub.26444-ref14">14</xref>] 。Snijder等研究认为HPV感染早于端粒酶基因水平上调，是端粒酶活化的原因 [<xref ref-type="bibr" rid="hanspub.26444-ref15">15</xref>] 。Aloysius 等也得出了同样的结果，并且发现HPV的作用十分迅速，在HPV的感染后的第一代细胞中就检测到端粒酶的活性 [<xref ref-type="bibr" rid="hanspub.26444-ref16">16</xref>] 。Hopman等也通过应用FISH方法检测CINII/III、微浸润癌和浸润性宫颈癌的hTERC基因和HPV整合，发现在HPV整合的双倍体病变中，80%可见hTERC基因增加，且在hTERC基因增加的病例，HPV整合突出，提示了HPV整合与hTERC基因扩增的平行及一致性。结合以往研究，人们推测端粒酶基因及端粒酶的激活可能是HPV致癌机制中的重要环节，继发于HPV感染的宫颈上皮病变的发生仍需要端粒酶基因扩增的参与作为首要补充；且这种基因的改变先于恶性基因转变并伴随着从ASCUS至CINIII的进展，是宫颈病变的早期事件 [<xref ref-type="bibr" rid="hanspub.26444-ref17">17</xref>] 。</p></sec><sec id="s7"><title>5. 宫颈HPV的型别和宫颈癌</title><p>人类乳头瘤病毒有120多种类型，高危型与癌前期病变和宫颈癌有关，近12~15种类型被归类于致癌基因的类型，近年来国内外的研究提示HPV不同亚型对宫颈上片细胞的致病力不同，而且存在较大差异。Hwang [<xref ref-type="bibr" rid="hanspub.26444-ref18">18</xref>] 等报导了不同级别宫颈病变组织(CINI轻度不典型增生，CINII中度不典型增生，CINIII重度不典型增生和(或)原位癌，感染HPV常见亚型(感染率依此递减)，CINI中为HPV16，18，39，35，51，52，56，66。CINII为HPV35，58，16，18，33，66，51，52。CINIII中为HPV16，31，58，33，39，51，52，18。其中50%的宫颈癌与HPV16感染有关。HPV16在CINIII中阳性率为68%,在微浸润宫颈癌中为93%。宿主染色体的不稳定性是由于HPV16整合插入还是HPV16协同？促进了其他类型HPV，引起了抑制抑癌基因更严重的不稳定性？E6、E7高表达，端粒酶的激活，导致肿瘤发生。</p><p>综上所述，HPV感染的型别不同，致病力也不同，其与hTERC基因的扩增有无相对应的关系，对疾病的进展有无指导意义，有待于进一步的研究，宫颈癌是一种以HPV感染为关键因子，多因素共同作用导致的恶性肿瘤，探讨HPV感染的型别、hTERC基因异常与宫颈病变进展的关系，希望为宫颈癌的预防、治疗、预后提供新的依据。</p></sec><sec id="s8"><title>文章引用</title><p>杨 梅,宁 旦. 宫颈端粒酶hTERC基因的表达和宫颈高危型HPV感染的型别的相关研究 Research on Expression of Telomerase hTERC Gene and Infection of High Risk HPV in Cervix[J]. 亚洲肿瘤科病例研究, 2018, 07(04): 51-55. https://doi.org/10.12677/ACRPO.2018.74008</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26444-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Knudson, A.G. (1985) Hereditary Cancer, Oncogenes, and Antioncogenes. Cancer Research, 45, 1437-1443.</mixed-citation></ref><ref id="hanspub.26444-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chung, G.T.Y., Huang, D.P., Lo, K.W., et al. (1992) Genetic Lesionin the Carc Inogenesis of Cervicalcancer. Anticaner Research, 12, 1485-1490.</mixed-citation></ref><ref id="hanspub.26444-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Mitra, A.B., Murty, V.S., Li, R.G., et al. (1994) Chaganti, Allelotype Analysis of Cervical Carcinoma a. Cancer Re-search, 54, 4481-4487.</mixed-citation></ref><ref id="hanspub.26444-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Rhyn, M.S. (1995) Telomere, Telomerase and Immortality. Journal of the National Cancer Institute, 87, 884-894.  
&lt;br&gt;https://doi.org/10.1093/jnci/87.12.884</mixed-citation></ref><ref id="hanspub.26444-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hoijt, S.E. and Shag, J.W. (1999) Role of Telomerase in Cellular Proliferation and Cancer. Journal of Cellular Physiology, 180, 10-18. &lt;br&gt;https://doi.org/10.1002/(SICI)1097-4652(199907)180:1&lt;10::AID-JCP2&gt;3.0.CO;2-D</mixed-citation></ref><ref id="hanspub.26444-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Tee, Y.T., Wang, P.H., Yang, S.F., et al. (2008) Lymph Node Metastases Not Human Telomerase Reverse Transcriptase or p53 Proteins, a the Strongest Prognostic Factor for Survival in Early Stage Cervica Cancer. Journal of Obstetrics and Gynaecology Research, 34, 1002-1009. &lt;br&gt;https://doi.org/10.1111/j.1447-0756.2008.00861.x</mixed-citation></ref><ref id="hanspub.26444-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Kloth, J.N., Oosting, J., van Wezel, T., et al. (2007) Combine Array Comparative Genomic Hybridization and Single Nucleotid Polymorphism Loss of Heterozygosity Analysis Reveals Complegenetic Alterations in Cervical Cancer. BMC Genomic, 20, 53-54.</mixed-citation></ref><ref id="hanspub.26444-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J.L. and Greyer, C.W. (2004) Telomerase RNA Structure and Function Implication for Dys-Keration Congenital. Trends in Biochemical Sciences, 29, 183-190. &lt;br&gt;https://doi.org/10.1016/j.tibs.2004.02.003</mixed-citation></ref><ref id="hanspub.26444-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Blasco, M.A. and Greid, E.R. (1997) Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA. Cell, 5, 25234.</mixed-citation></ref><ref id="hanspub.26444-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">高宗侠, 凌斌. 人乳头瘤病毒、端粒酶、染色体异常与宫颈癌关系的研究进展[J]. 中国临床保健杂志, 2007, 3(10): 325-327.</mixed-citation></ref><ref id="hanspub.26444-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lee, D.K., Kim, B.C., Kim, I.Y., et al. (2002) The Human Papilloma Virus E7 Oncoprotein Inhibits Transforming Growth Factor-Be-Tasignaling by Blocking Binding of the Smad Complex to Its Target Sequence. The Journal of Biological Chemistry, 277, 38557-38564. &lt;br&gt;https://doi.org/10.1074/jbc.M206786200</mixed-citation></ref><ref id="hanspub.26444-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Favre Bonvin, A., Reynaud, C., Kretz Remy, C., et al. (2005) Human Papilloma Virus Type 18 E6 Protein Binds the Cellular PDZ Protein TIP-2/GIPC, Which Is Involved in Transforming Growth Factor Beta Sig-naling and Triggers Its Degradation by the Proteasome. Journal of Virology, 79, 4229-4237. &lt;br&gt;https://doi.org/10.1128/JVI.79.7.4229-4237.2005</mixed-citation></ref><ref id="hanspub.26444-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Mark, R.P., Trent, H., Roger, D.P., et al. (2006) Selection of Cervical Keratinocytes Containing Integrated HPV16 Associates with Episome Loss and an Endogenous Antiviral Response. PNAS, 103, 3822-3827.  
&lt;br&gt;https://doi.org/10.1073/pnas.0600078103</mixed-citation></ref><ref id="hanspub.26444-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Snijder, P.J., Van, D.M., Walboomer, J.M., et al. (1998) Telomerase Activity Exclusively in Cervical Carcinomas and Subset of Cervical Intraepithelial Neoplasia Grade III Lesions: Strong Association with Elevated Messenger RNA Levels of Its Catalytic Subunit and High Risk Human Papillomavirus DNA. Cancer Research, 58, 3812-3818.</mixed-citation></ref><ref id="hanspub.26444-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Aloysius, J., Klingelhutz, S.A., et al. (1996) Telomerase Activation by the E6 Gene Product of Human Papilloma-virus Type 16. Nature, 380, 791.</mixed-citation></ref><ref id="hanspub.26444-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hopman, A.H., Theelen, W., Hommelberg, P.P., et al. (2006) Genomic Integration of Onco-genic HPV and Gain of the Human Telomerase Gene TERC at 3q26 are Strongly Associated Events in the Progression of Uterine Cervical Dysplasia to Invasive Cancer. The Journal of Pathology, 210, 412-419. &lt;br&gt;https://doi.org/10.1002/path.2070</mixed-citation></ref><ref id="hanspub.26444-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Heselmeyer-Haddad, K., Sommerfeld, K., White, N.M., et al. (2005) Genomic Amplifi-cation of the Human Telomerase Gene (TERC) in Pap Smears Predicts the Development of Cervical Cancer. American Journal of Pathology, 166, 1229-1238. &lt;br&gt;https://doi.org/10.1016/S0002-9440(10)62341-3</mixed-citation></ref><ref id="hanspub.26444-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Hwang, T.S., Jeong, J.K., Park, M., et al. (2003) Detection and Typing of HPV Genotypes in Various Cervical Lesions by HPV Oligonucleotide Microarray. Gynecologic Oncology, 90, 51. &lt;br&gt;https://doi.org/10.1016/S0090-8258(03)00201-4</mixed-citation></ref></ref-list></back></article>